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DPC4 (deleted in pancreatic cancer 4)/Smad4 is an essential factor in transforming growth factor (TGF)-b signaling and is also
knownasafrequentlymutatedtumorsuppressorgeneinhumanpancreaticandcoloncancer.However,consideringthefactthat
TGF-b can contribute to cancer progression through transcriptional target genes, such as Snail, MMPs, and epithelial–
mesenchymal transition (EMT)-related genes, loss of Smad4 in human cancer would be required for obtaining the TGF-b
signaling-independentadvantage,whichshouldbeessentialforcancercellsurvival.Here,weprovidetheevidencesaboutnovel
role of Smad4, serum-deprivation-induced apoptosis. Elimination of serum can obviously increase the Smad4 expression and
induces the cell death by p53-independent PUMA induction. Instead, Smad4-deﬁcient cells show the resistance to serum
starvation.InducedSmad4suppressesthePAK1,whichpromotesthePUMAdestabilization.WealsofoundthatSiah-1andpVHL
areinvolvedinPAK1destabilizationandPUMAstabilization.Infact,Smad4-expressedcancertissuesnotonlyshowtheelevated
expressionofPAK1,butalsosupportourhypothesisthatSmad4inducesPUMA-mediatedcelldeaththroughPAK1suppression.
Our results strongly suggest that loss of Smad4 renders the resistance to serum-deprivation-induced cell death, which is the
TGF-b-independent tumor suppressive role of Smad4.
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Human cancer progression is driven by accumulation of
genetic mutation.
1 According to the multistep carcinogen-
esis model of pancreatic and colon cancer,
2,3 oncogenic
mutation of K-Ras, p16 inactivation by methylation or
deletion, and Smad4 deletion occur in pre-carcinoma
stage.
4,5 Considering the fact that Smad4 deletion or
mutation occurs in juvenile polyposis coli,
6 it is clear that
Smad4 exerts the critical tumor suppressor function. In
previous, we have suggested that oncogenic K-Ras, which
is mutated in early adenoma stage, can suppress the p53
function.
7,8 Thus, cell proliferation ability of oncogenic
K-Ras may be appeared in pre-cancerous pancreatic epithelial
cells. In addition, p16 inactivation can render the resistance to
transforming growth factor (TGF)-b-induced or pRB-mediated
cell cycle inhibition.
9,10 Hence, further genetic mutations of
TGF-b signaling components seem to be not essential for
cancer progression. Moreover, Smad4, but not TbRI, II, or
R-Smadis frequentlymutatedin human colon,and pancreatic
cancerhasnotbeenclearlydemonstrated.AsTGF-bcanalso
contribute to epithelial–mesenchymal transition (EMT) pro-
gression through transcriptional target genes, such as Snail,
MMPs, and EMT-related genes,
11,12 it seems to be not
reasonable that cancer cells inactivate Smad4 to gain the
resistance to TGF-b signaling. Instead, loss of Smad4 in
human cancer would provide that TGF-b signaling-indepen-
dent advantage, which should be essential for cancer cell
survival.
During colon or pancreatic cancer progression, Smad4
deletion occurs at late hyperplasia or carcinoma stage,
wheretumorvolumeisincreased.
2,3Thus,innercellmassof
tumorwouldbesufferedbynutrientdeprivationandhypoxia.
To overcome this, cancer cell should develop the defense
mechanism. One of plausible and required event seems to
be inactivation of apoptosis mechanism. In this study, we
investigate the relevance of Smad4 and nutrient-depriva-
tion-induced apoptosis. Here, we provide the several
evidences about involvement of Smad4 in serum starva-
tion-induced cell death, which is mainly achieved by
induction of PUMA. Although PUMA is an immediate-early
target gene of p53,
13,14 w eﬁ n dt h a ti n d u c t i o no fP U M Ai s
achieved by p53-independent mechanism. Instead, Smad4
induces PUMA through suppression of PAK1, which is
elevated in Smad4-positive human colon cancer tissues.
Our results suggest that Smad4 exerts the novel tumor
suppressive function through PUMA induction and PAK1 is
worked as intrinsic inhibitor against Smad4-induced cell
death.
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Induction of Smad4 in response to serum starvation. To
address the role of Smad4 during cancer progression,
we investigated the expression of Smad4 in colon cancers
and found that Smad4 reduction occurs at transition stage
from adenoma to carcinoma (Supplementary Figure 1a,
Supplementary Table 1). As carcinoma cells are resistant
to nutrient and oxygen deprivation, we tested the role of
Smad4 in response to serum starvation and hypoxic stress.
Interestingly, Smad4 expression was obviously induced by
serum starvation, but not by hypoxic stress (Supplementary
Figure 1b). We also measured the expression of p53, p21
and PUMA, because serum starvation and hypoxic stress
can activate p53. Although p53 and p21 were induced by
hypoxic stress, PUMA showed the Smad4-dependent
manner (Supplementary Figure 1b). We also measured
the expression of Smad4 and PUMA under serum-free (SF)
condition in HCT116 and its isogenic Smad4-deﬁcient
cells, and obtained the same result that PUMA induction
was achieved by Smad4-dependent manner (Figure 1a).
We also checked the Smad4 expression in four kinds of
human cancer cell lines, and found that Smad4 in three
kinds of cell lines were induced by serum starvation at post-
transcription level (Figure 1b). From the extended study,
we found that Smad4 induction was a general event for cell
lines, except for some kinds of cell lines, such as MKN45
and SK-N-SH (Supplementary Figure 1c). As MKN45 is a
gastric cancer cell line, we checked the Smad4 induction
in gastric cell lines. However, all of tested cell lines,
except MKN45, showed the response to serum starvation
(Supplementary Figure 1d). Next, we monitored the Smad4
expression in neuron cell and leukemia cell line. In these
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Figure 1 Induction of Smad4 in response to serum starvation. (a) Induction of Smad4 and PUMA in response to SF condition. HCT116 and its isogenic Smad4-deﬁcient
cells were incubated in SF conditionfor indicating time. Actin was used as loading control. (b) Serumstarvation leads to Smad4 inductionin three kinds of cell lines, but not in
MKN45,atpost-transcriptionlevel.Smad4expressionwasdeterminedbyWBanalysisattranslationlevelandbyreversetranscription(RT)-PCRanalysisattranscriptionlevel.
(c) Induction of Smad4 is observed in normal ﬁbroblast. Normal human ﬁbroblast was exposed to SF condition for indicating time, and the Smad4 expression level was
evaluated by WB. (d) Serum starvation-induced Smad4 is accumulated in cytosol. After ﬁxation with Me-OH, cells were stained with anti-Smad4 (green) and 406-diamidino-2-
phenylindole(DAPI;blue). (e) Smad4 is retainedin cytosol.HCT116cells were divided into four subcellular fractions usinga Subcell kit (Calbiochem), andthe expressionsof
Smad4 were examined. (f) Smad4-deﬁcient HCT116 cells showed resistance to SF condition compared with positive cells, but in the presence of DNA-damaging agent,
adriamycin (Adr; 2mg/ml), both cells revealed similar sensitivity. Cell viability was determined by MTT assay
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Cell Death and Diseasecell lines, we did not observe the induction of Smad4
including K562 (Supplementary Figures 1e and f). We
could observe the induction of Smad4 in response to serum
starvation in normal cell (Figure 1c), indicating that SF
condition-induced Smad4 is a general event. As Smad4
is a well known transcription factor, we determined the
localization of Smad4 through immunoﬂuorescence stain-
ing and cell fractionation assay. However, serum-deprivation-
induced Smad4 was retained in cytosol (Figures 1d and e).
To address the biological meaning of Smad4 induction,
we measured the cell viability of HCT116 and HCT116
Smad4 / cell lines
15 in SF condition and found that
Smad4 /  cell showed the resistance to SF condition-
induced cell death, whereas these cell lines showed the
similar response to DNA damaging agent, adriamycin
(Figure 1f). This result indicates that Smad4 would be not
related with DNA damage-induced cell death pathway.
TGF-b signaling-independent Smad4 induction by serum
starvation. To reveal the induction mechanism of Smad4, we
checked the involvement of TGF-b signaling. Blocking of
R-Smad using siRNA or activation TGF-b signaling, using
constitute active TbR1 transfection, did not alter the Smad4
expression (Supplementary Figures 2a and b). In addition,
overexpression of inhibitory Smad, Smad7, or treatment of
TGF-b neutralizing antibody could not block the SF-induced
Smad4 expression (Supplementary Figures 2b and c).
Other kinds of TGF-b signaling components did not also
show the relevance with Smad4 induction by SF condition
(Supplementary Figure 2d). As human or bovine serum
contains growth factors, we checked the other possibi-
lity such as growth factor deprivation. However, IGF-1 did
not block the Smad4 induction by serum starvation
(Supplementary Figure 3a). In addition, mitochondria ATP
synthesis blockers (cyclosporin A and oligomycin) did not
induce Smad4 in serum-present condition, indicating that
induction of Smad4 would not be triggered by energy
deprivation (Supplementary Figure 3b). Instead, puriﬁed BSA
could block the induction of Smad4 (Supplementary Figure 3c).
These results indicate that extracellular nutrient concentration
is critical for Smad4 induction.
E-cadherin regulates SF-induced Smad4. As E-cadherin
(E-cad)-mutated MKN45
16 and leukocytes, which do not
express E-cad,
17 did not respond to SF (Figure 1b,
Supplementary Figures 1e and f), we speculated that E-cad
is involved in Smad4 induction. Consistent with our
hypothesis, dominant-negative (DN)-E-cad could block the
SF induction of Smad4 as well as PUMA (Figure 2a). Hence,
we tested the interaction between Smad4 and E-cad, and
revealed that Smad4 was released from E-cad under SF
condition by immunoprecipitation (IP) and GST pull-down
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Figure 2 E-cad is involved in Smad4 regulation. (a) Blocking the E-cad reduces the Smad4 induction in response to SF condition. PC3 cells were transfected with empty
vector (EV), E-cad, DN-E-cad (DN-E), and siRNA Smad7. (b) Interaction between Smad4 and E-cad was decreased in SF condition. At 24h after transfection, HEK293 cell
lysates were immunoprecipitated with anti-Smad4 and analyzed by WB. (c) Smad4 is released from E-cad in SF condition. GST–E-cad was incubated with Smad4–FLAG-
transfected HEK293 cell lysates in RIPA buffer for 2h. After washing, precipitated protein was subjected to SDS-PAGE and WB with the indicated antibodies. (d) Interaction
betweenSmad4andE-cadisaspeciﬁcevent.GSTpulldown-wasperformedwithseveralproteins,andeachproteinwasanalyzedbydetectableantibodies(datanotshown).
(e) In the serum-deﬁcient condition, Smad4 induction is only shown in AGS cells (containing wild-type E-cad), but not in mutant E-cad harboring MKN45. Each cell line was
exposed to SF condition for indicated times, and Smad4 and E-cad proteins were detected by WB
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Cell Death and Diseaseassay (Figures 2b and c). To conﬁrm this, we performed the
GST pull-down again with several kinds of proteins and found
that Smad4–E-cad binding was speciﬁc (Figure 2d). In fact,
serum starvation-induced Smad4 was not detected in MKN45
but in AGS cell (wild-type E-cad; Figure 2e). These results
indicate that SF-induced Smad4 is achieved by dissociation
from E-cad and provide the explanation about the insensitivity of
Smad4 induction in neural cells, which possesses N-cadherin
and leukemia cell lines (Supplementary Figures 1e and f).
Smad4 induces PUMA. Next, we focused on induction of
PUMA as the cell death mechanism (Figure 1a). As PUMA
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Figure 3 Smad4 induces PUMA. (a) PUMA is induced by Smad4 in response to SF condition. PUMA expression level is signiﬁcantly decreased not only in p53-deﬁcient cells but
also in Smad4-deﬁcient cells. Expression of indicat e dp r o t e i n si nH C T 1 1 6c e l l sw a sa s s e s s e db yW B .( b) Smad4-dependent induction of PUMA. PUMA induction was not detected in
Smad4-deﬁcient Capan-1 cells. (c) Overexpression of Smad4 induces PUMA expression. HEK293 cells were transfected with empty vector (EV) and Smad4, and indicating proteins
were detected by WB analysis. (d) Smad4 transfection can restore the SF-induced cell death in Smad4-deﬁcient Capan-1. Cells were transfected with EV and Smad4 for 24h, and
viability in different serum concentration was determined by MTT assay. (e and f) Absence of apoptosis in PUMA-deﬁcient HCT116. HCT116 (PUMAþ/þ) and its isogenic PUMA-
deﬁcientcells(PUMA / )wereincubatedinSFconditionfor24or48h(f).Dyingcellswerecountedusingtrypanbluedyeexclusionassay.PUMAdeﬁciencydidnotaltertheSmad4
induction by SF condition (inset). (g) Extension of protein half-life of Smad4 and PUMA in SF condition. A549 cells were incubated in SF condition for 6h to adjust the starting protein
levels and were incubated in SF or complete media condition for indicated time with CHX (100mg/ml). (h) The half-life of the PUMA protein is remarkably increased in SF condition.
Expression level of PUMA was determined by densitometer. Presented graph showed the fold changes compared with control (CHX 0 time in SF condition)
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Cell Death and Diseasehas been identiﬁed as p53 target gene,
13,14 we checked the
expression of PUMA in p53  and Smad4  HCT116 cell
lines. Consistent with previous reports, PUMA expression
was low in p53-deﬁcient HCT116 (Figure 3a). However,
PUMA expression was also reduced in Smad4-deﬁcient cell
line (Figure 3a). In addition, it could be induced by serum
starvation for 6h in p53-deﬁcient cell but not in Smad4 cell
(Figure 3a). To conﬁrm it, we measured the expression of
Smad4 and PUMA in PC3 (p53 ), HCT116 and Capan-1
(Smad4 ) under SF condition and obtained the similar result
that induction of PUMA by SF condition is not related with
p53 but Smad4 (Figure 3b). We also observed the PUMA
induction by Smad4 transfection alone (Figure 3c). To extend
this, we measured the expression of PUMA in several kinds
of cell lines, including Smad4-deleted MDA-MB 468 and
p53-null PC3. In this experiment, we could observe the
induction of PUMA only in PC3, HCT116, and 293 cell lines,
but not in MKN45 and MDA-MB 468 (Smad4 ), by SF
treatment. In addition, despite of induction of Smad4, MIA-
Paca-2 and Panc-1 did not show the induction of PUMA
(Supplementary Figure 4a). These results indicate that
although PUMA induction was achieved by Smad4, there
would be additional regulation or inhibition mechanism
between Smad4 and PUMA. To exclude the relevance of
p53 in SF-induced PUMA, we monitored the expression of
PUMA after treatment of DNA-damaging agents (adriamycin
and etoposide) in HCT116 and HCT116 p53 /  cells.
Comparing with induction of PUMA by DNA-damaging
agents, more obvious induction of PUMA was detected in
p53 /  cells under SF condition (Supplementary Figure 4b).
We also measured the PUMA expression in various kinds of
p53 mutant-transfected cells. However, PUMA induction was
apparently increased by SF condition, regardless of p53
mutants (Supplementary Figure 4c). To verify the role of
Smad4 in SF-induced cell death, we transfected the Smad4
into Capan-1 (Smad4  cell) and monitored the cell viability.
Comparing with EV-transfected cells (the marginal
suppression of cell viability), viability of Smad4-transfected
cells was obviously reduced (Figure 3d). To get more clear
evidence, we measured the cell viability in PUMA-deﬁcient
HCT116
18 using trypan blue dye exclusion assay and
found that PUMA is essential for cell death in SF condition
(Figures 3e and f). To examine the regulation mechanism,
we measured the transcript of PUMA. However, serum
starvation did not induce the PUMA transcript or pro-
moter activity (Supplementary Figures 5a and b). Instead,
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Cell Death and DiseasePUMA expression was increased in cytosol (Supplementary
Figure 5c). Hence, we next checked the PUMA protein
stability. Through pulse-chase analysis, we found that protein
stability of PUMA and Smad4 was obviously extended by
serum starvation (Figures 3g and h). This result may provide
the evidence that Smad4 regulation was achieved at post-
transcription level. We could conﬁrm it using PC3 and
HCT116 cell lines (Supplementary Figures 5d–f). In fact,
Smad4 half-life was extended from 2h to up to 10h,
and PUMA half-life was also extended about twofolds
(Figure 3g and Supplementary Figure 5f). To address
the molecular mechanism about Smad4-induced PUMA
stabilization, we tested the interaction between PUMA and
Smad4. However, we did not observe the interaction between
them (Supplementary Figure 5g). Hence, we checked the effect
of ER stress because it can induce PUMA expression in a
p53-independent manner.
19 Although ER stress could
induce PUMA, it did not increase the Smad4 expression
(Supplementary Figure 5h). This result suggests that there
would be novel PUMA-induction mechanism, which is not
related with p53 or ER stress.
Smad4 regulates PUMA through PAK1 suppression. To
explore the mechanism about Smad4-induced PUMA
stabilization, we performed the chemical inhibitor screening
and found that AG879 could induce PUMA in serum-
containing condition (Supplementary Figure 6a). In addition,
this chemical could induce Smad4 expression
(Supplementary Figure 6b). As AG879 is known to be an
inhibitor of PAK1, which regulates cell mobility and G
proteins,
20 and is known to interact with Smad4,
21 it seems
to be a putative linker between Smad4 and PUMA. To
investigate the relevance between PAK1–Smad4 or PAK1–
PUMA, we checked the expression of PAK1 in SF condition.
In PC3 cells, SF could induce Smad4 and PUMA and
suppress the PAK1 (Figure 4a). In contrast, Capan-1 did
not show the reduction of PAK1 or induction of
PUMA (Figure 4a). As PAK1 can be inhibited by
autophosphorylation,
4,22 we checked the p-PAK1 and found
that SF condition could induce p-PAK1 (Figure 4b). Next, we
measured the expression of PAK1 in Smad4 /  HCT116
and revealed that Smad4 could suppress PAK1 expression
(Figure 4c). To reveal the effect of PAK1 on PUMA expression,
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Cell Death and Diseasewe transfected the Smad4 and found that Smad4 over-
expression could suppress the PAK1 expression and induce
PUMA, whereas PAK1 overexpression could block the PUMA
induction by SF or Smad4 overexpression (Figure 4d). Instead,
si-Smad4 could induce PAK1 expression (Figure 4e). We also
checked the effect of mutant PAK1 on PUMA regulation.
Kinase-dead PAK1 (which is point mutant at K299 residue to R)
and H/L PAK1 (N-terminal G-protein binding domain mutant at
H83L and H86L) were regulated by Smad4, whereas they did
not suppress the PUMA expression
23 ( F i g u r e4 e ) .I nf a c t ,P A K 1 -
KD and H/L mutants did not block the SF-induced PUMA
induction (Figure 4f, and Supplementary Figure 6c). Our results
suggest that Smad4 induces PUMA expression through PAK1
suppression.
PAK1 regulates SF-induced cell death and PUMA
expression. We next checked the effect of PAK1 on
SF-induced cell death and revealed that PAK1, but not mutant
PAK1, blocked it (Figure 5a). Indeed, PAK1 could reduce the
half-life of PUMA (Figure 5b). To conﬁrm the effect of PAK1
on SF-induced cell death and PUMA induction, we measured
the expression of PAK1, PUMA, and Smad4 in MIA-Paca-2,
MCF-7, and MDA-MB 468 (Smad4-null cell). Interestingly,
MIA-Paca-2 showed the elevated expression of PAK1
(Figure 5c and Supplementary Figure 6d) and resistance to
SF-induced cell death and PUMA (Figures 5c and d, and
Supplementary Figure 6e). Considering the result that MDA-
MB 468 was also resistant to SF-induced PUMA induction
and cell death (Supplementary Figures 6d and e), PAK1
overexpressed cells could acquire the resistance to
SF-induced cell death and PUMA like Smad4-deﬁcient
condition. To conﬁrm the role of PAK1 on PUMA
regulation, we knocked down the PAK1 through siRNA and
measured expression of PUMA and cell viability of
MIA-Paca-2. Elimination of PAK1 could restore the PUMA
induction in response to SF condition (Figure 5c) and
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Figure 6 Direct interaction between PUMA and PAK1–Smad4. (a) PAK1 interacts with Smad4 and PUMA. HEK293 lysate overexpressing wild-type PAK1 (Myc tagged)
was used for IP, which was performed with anti-Myc. PAK1 can bind to both Smad4 and PUMA, but overexpression of Smad4 attenuates PAK1 and PUMA interaction.
(b) PAK1 binds to Smad4 MH1 domain. Agarose bead-conjugated GST–Smad4 (MH1) was incubated with PAK1-transfected HEK293 lysates, and Smad4-associated PAK1
was determined by WB after precipitation. Tubulin was used as a negative control. (c) N terminus of PAK1 is essential to bind to Smad4. GST pull-down was performed
with PAK1 N- and C- terminal fragments. (d) Both wild and mutant PAK1 can bind to PUMA. PAK1 (Myc tagged) expressing HEK293 lysates were used for GST pull-down.
(e) Interaction map between Smad4 and PAK1 and PUMA–PAK1. MH1 domain of Smad4 bound to and protected the PAK1-N-terminal domain-induced PUMA suppression.
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from media. Expression of indicating proteins were examined by WB analysis
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Cell Death and Diseasepromote the cell death (Figure 5d). In addition, si-PAK1 could
induce PUMA expression in Smad4-deﬁcient cell lines
(Capan-1 and Panc-1; Figure 5e). These results indicate
that PAK1 suppresses the PUMA expression through its
enzymatic activity.
Direct interaction of Smad4–PAK1 and PAK1–PUMA. To
get more detail mechanism, we performed the IP and reve-
aled that PAK1–Smad4 pr-PAK1–PUMA could associate
with each other (Figure 6a and Supplementary Figure 7a).
Moreover, interaction between PAK1 and PUMA was
reduced by Smad4 overexpression (Figure 6a). To conﬁrm the
direct binding between PAK1 and Smad4, we performed the
GST pull-down with Smad4 MH1 domain
24 and found that
PAK1, regardless of mutants, could associate with Smad4
(Figure 6b). We could conﬁrm the interaction by IP analysis
(Supplementary Figure 7b). Using two kinds of recombinant
PAK1, PAK1-N (N-terminal G-protein binding domain;
70–149AA) and PAK1-C (kinase domain; 249–545), we could
determine the PAK1-N as Smad4 binding domain (Figure 6c).
We could also observe the direct interaction between PAK1
and PUMA through GST pull-down and IP methods (Figure 6d).
Moreover, PAK1 mutants also showed the interaction with
PUMA with stronger afﬁnity than wild-type PAK1 (Figure 6d),
suggesting that enzymatic activity of PAK1 would be involved
in PUMA regulation. To determine the binding domain of
PAK1 with PUMA, we performed the GST pull-down again
using PAK1-N and -C domains. Differentially from Smad4,
both domains were involved in interaction with PUMA
(Supplementary Figure 7c). However, when we used the
endogenous PUMA, PAK1-N showed obvious interaction with
PUMA (Supplementary Figure 7d), indicating that N-terminal
domain of PAK1 would be more important for binding with
PUMA. To conﬁrm the binding between Smad4–PAK1–PUMA
and test the binding speciﬁcity, we performed the GST pull-
down again and found the speciﬁc binding of PAK1–Smad4 and
PUMA–PAK1 (Supplementary Figure 7e). However, Siah-1 and
pVHL did not associate with Smad4 or PUMA (Supplementary
Figure 7e). In contrast, PAK1 showed the binding afﬁnity with
Siah-1 and pVHL, E3 ligase (Supplementary Figure 7f).
Considering our results, Smad4 MH1 domain can bind to
PAK1 N-terminal domain and block the PAK1-induced PUMA
suppression, whereas PAK1 can suppress the PUMA
expression through N-terminal domain. Thus, Smad4, induced
by SF, protected the PUMA from PAK1-induced suppression
(Figure 6e).
pVHL and Siah-1 involved in Smad4-induced PAK1
suppression. Next, we checked the involvement of E3
ligases on Smad4-mediated PAK1 and PUMA regulation.
Overexpression of Siah-1 could suppress the PAK1
expression, whereas si-Siah-1 could block the Smad4-
mediated PAK1 suppression (Supplementary Figure 8a). In
addition, Siah-1 could induce PUMA expression
(Supplementary Figure 8b). However, Siah-1 did not alter
the SF-induced Smad4 (Supplementary Figures 8a and b).
Next, we checked the effect of pVHL on PUMA expres-
sion and obtained that pVHL could increase the PUMA
expression (Supplementary Figure 8c). To conﬁrm this,
we reperformed the similar experiment and obtained the
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Figure 7 ElevatedexpressionofPAK1inSmad4-positivecoloncancertissues.(a)AnalysisofPAK1expressionin489humancoloncancertissuesusingIHCanalysis.In
Smad4-intact tissues, PAK1 expression was elevated. (b) PAK1 expression is elevated in Smad4-negative tissues. More detail clinicopathological data were available in
Supplementary Table 2. (c) Diagram for summary. In response to serum deprivation, Smad4 is induced by releasing from E-cad and suppresses PAK1-mediated PUMA
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expression and enhance the PUMA response to SF condition
(Figure 6f).
Elevated expression of PAK1 in Smad4 wild-type
cancers. Considering our results, functional defect of
Smad4, including PAK1 overexpression, may require for
survival of cancer cell in nutrient-deﬁcient condition. To verify
this, we examined the expression of Smad4 and PAK1
through IHC in 489 colon cancer tissues using tissue array
(Supplementary Figures 9 and 10; clinicopathological
information is available in Supplementary Table 2). In
normal intestinal tissue, Smad4 was highly expressed in
bottom of crypt, whereas PAK1 was highly detected in apical
area of villi, reversely (Supplementary Figure 9). This result
was consistent with our data that Smad4 suppressed the
PAK1 expression. However, in cancer tissues, we obtained a
quite different feature that PAK1 expression is increased in
Smad4-positive cancers (Figures 7a and b). This result
suggests that in human cancer PAK1 overexpression can
overwhelm the Smad4-indued apoptosis, which would be a
survival strategy for Smad4-positive cancer cells.
Discussion
Smad4 is a well-known TGF-b signaling component and
tumor suppressor gene.
5,6,9 TGF-b inhibits cell proliferation
by regulation of c-myc and p15/INK4B, p27, and p21. Upon
TGF-b, phosphorylated R-Smads (such as Smad2 and
Smad3) by receptor kinase are formed the complex with
Smad4 and translocated into nucleus, where Smad complex
works as a transcription factor. Thus, in many kinds of human
cancers genetic mutations in TGF-b signaling components
are reported. One of them is genetic mutation of Smad4,
deletion or mutation of which occurs frequently in human
colon and pancreatic cancers. However, TGF-b signaling
also possesses oncogenic property through promoting the
EMT.
25 According to recent papers, TGF-b-driven EMT is
also achieved by transcriptional activity of Smads.
26 Indeed,
TGF-b signaling seems to be essential for cancer metastasis,
and EMT and Smad4 are core components in this signaling
cascade.ThequestionisremainedhowSmad4-deﬁcientcells
can enter the EMT for metastasis and Smad4 deletion or
inactivation is required for TGF-b signaling inactivation.
Considering that pancreatic and colon cancer shows highly
aggressive phenotype and easily enter the EMT stage, there
would be additional EMT-promoting mechanism. Recently, it
has been suggested that Smad4 can serve as a barrier
against cancer growth and metastasis in prostate cancer.
27
This result is consistent with our result because nutrient or
serum deprivation occurs in core region of tumor mass,
28
which can be easily converted into aggressive and invasive
carcinoma. Considering our result that Smad4 is signiﬁcantly
induced by serum starvation (Figures 1a and b), physiological
function of Smad4 would be a barrier for the too largely
increasing tissue mass to be supported by the circulation
system or nutrient-supplying system. However, growth of
cancer cells or pre-cancerous adenoma cells is too rapid. At
this point, Smad4 may suppress the cell growth by PUMA-
mediated apoptosis program (Figure 7c). Thus, in Smad4-
intact condition, pre-cancerous cells, which are located far
from blood vessel, are eliminated and cancer progression
would be halted. In contrast, Smad4-deﬁcient cells show
resistance and are converted into carcinoma.
Considering the fact that defect of Smad4 occurs in 50% of
pancreatic cancers, there would be additional tumorigenic
pathway, which can overcome the nutrient deprivation-
inducedcelldeath,suchasPAK1overexpression(Figure7c).
In fact, elevated expression of PAK1 following cancer pro-
gression has been reported.
29 We also found that PAK1
blocks the PUMA induction and SF-induced cell death
(Figures 4 and 5). In addition, we could observe the induction
of PAK1 in Smad4-expressed cancer tissues (Figures 7a
and b). These results indicate that overexpression of PAK1
can overcome the Smad4-induced apoptosis.
In this study, we show the importance of PUMA in SF-
induced cell death. Although genetic mutation of PUMA has
not been reported frequently in human cancer, in a study
involving an animal model, PUMA /  mice showed sensitiv-
ity to colon cancer incidence,
30 suggesting that PUMA also
functions as tumor suppressor. We also showed the involve-
ment of Siah-1 and pVHL in PAK1–PUMA regulation
(Figure 6f). Considering the previous reports that pVHL is
frequentlydeletedinhumanrenalcell carcinoma
31andSiah-1
possesses tumor suppressor potentials,
32 genetic or epige-
netic defects in pVHL or Siah-1 may also enhance the PAK1
expression and weaken the Smad4–PUMA axis. Although
more accumulated evidences are required, reduction of pVHL
or Siah-1 would be one of the reasons for elevated expression
of PAK1 in human cancer, which may lead to disruption of
Smad4-induced cell death.
Collectively, human epithelial cells, located far from blood
vessel or nutrients, are eliminated by Smad4–PUMA system,
which can be overcome in cancer by Smad4 deletion or PAK1
overexpression. These results will provide the basis for
development of smart anti-cancer drug such as speciﬁc
inhibitor of PAK1 and PUMA.
Materials and Methods
Cell lines and reagents. Cell lines used in this research were obtained from
the American Type Culture Collection (Manassas, VA, USA) or Coriell Cell
Repositories (normal ﬁbroblast; GM00038, Coriell Cell, Camden, NJ, USA) and
maintainedinRPMI-1640,DMEM,orMEMcontaining10%FBSandantibiotics.For
serum starvation, cell lines were incubated with SF media for indicating times.
General reagents were provided by Sigma (St. Louis, MO, USA). Chemical
inhibitors were purchased from Calbiochem (St. Louis, MO, USA). IGF-1 and TGF-
b-neutralizing antibody were obtained from R&D Systems (Minneapolis, MN, USA).
Western blot analysis, IP, and GST pull-down assays. Proteins are
extracted from cells by radioimmunoprecipitation assay (RIPA) buffer. Samples
were applied to SDS-PAGE, and western blotting (WB) analysis was performed by
means of general protocol. Blotted membranes were incubated with primary
antibodies detecting Smad4 (B-8; 1/1000; Santa Cruz Biotechnology, Santa Cruz,
CA, USA), PUMA (PC686; 1/5,00; Calbiochem), PAK1 (2602; 1/1000; Cell
Signaling Technology, Danvers, MA, USA), p-PAK1 (2605; 1/1000; Cell Signaling
Technology), actin (I-19; 1/1000; Santa Cruz Biotechnology), E-cadherin (G-10;
1/500; Santa Cruz Biotechnology), a-tubulin (TU-02; 1/1000; Santa Cruz
Biotechnology), FLAG (F3165; 1/1000; Sigma), Myc (clone 9E10; 1/1000;
Sigma), p53 (DO-1; 1/5000; Santa Cruz Biotechnology), p21 (2946; 1/1000; Cell
Signaling Technology), GST (B-14; 1/1000; Santa Cruz Biotechnology), and Cox-2
(C-20; 1/1000; Santa Cruz Biotechnology). Secondary antibodies were HRP-linked
goat anti-mouse, goat anti-rabbit, and mouse anti-goat antibodies (all 1/10000;
Pierce, Thermo Fisher Scientiﬁc Inc., Rockford, IL, USA). The whole-cell lysates
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agarose beads (Invitrogen, Carlsbad, CA, USA) for 2h. After centrifugation and
washing with phosphate-buffered saline (PBS) and RIPA, the immunocomplexes
were applied to SDS-PAGE and WB analysis. To determine the direct interaction
between proteins, agarose bead-conjugated GST–Smad4 (MH1), PUMA, PAK1-N/
C fragment, and E-cad were incubated with cell lysates for 2h at 41C. Through the
same procedure with IP, precipitated proteins were determined by WB analysis.
More detail procedure for IP, WB, and GST pull-down are available in our previous
literatures.
7,8
Recombinant proteins. To produce the recombinant proteins, DNA
fragments encoding human PAK1 N-terminal domain (residues 70–149) and C-
terminal domain (residues 249–545) were ligated into the EcoRI and HindIII sites of
the pGEX-TEV vector, which is a modiﬁed vector made by adding a TEV protease
cleavage site to pGEX-4T1 (Invitrogen). Domains were determined according to
previous literature.
4 The full-length human PUMA (residues 1–193) also comprised
the same enzyme sites as the pGEX-TEV vector. The recombinant proteins were
expressed in the E. coli strain BL21 (DE3) as GST-fusion proteins. The proteins
were puriﬁed by glutathione-afﬁnity chromatography.
Transfection of mammalian expression plasmids and
siRNA. The mammalian expression plasmid encoding MH1-Smad4,
24 PUMA,
PUMA-Luc,
14 wild and mutant type of PAK1,
23 E-cad, and DN-E-cad
33 were
obtained from Addgene(Cambridge, MA, USA). For in vitro gene knockout, siRNAs
against target proteins were generated following previous literatures. Target
sequence of siRNA for each gene is described below: Smad4: 50-CA-
TTGGATGGGAGGC-30; PUMA: 50-TCTCATCATGGGACTCCTG-30; PAK1 no. 1:
50-TCTGTATACACACGGTCTG-30; PAK1 no. 2: 50-GGAGAAATTACGAAGCATA-30;
Smad2: 50-AATGGAGTGAGTATAGTCATCCAGA-30; Smad3: 50-AGATCTTCA
GGTTGCATCCTGGTGG-30; Smurf: 50-GATTCGAACCTTGCAAAGAAAGAC-30;
FAK1: 50-GCATGTGGCCTGCTATGGA-30; Smad7: 50-AAGCTCAATTCGGACAA
CAAG-3; Siah-1: 50-GATAGGAACACGCAAGCAA-30; and VHL: 50-AACTGAATT
ATTTGTGCCATC-30. Transfection was performed for 24h using Jei-pei reagent
(JetPEI; Polyplus Transfection, New York, NY, USA) according to the
manufacturer’s protocol.
Luciferase assay. To address the PUMA activity, PUMA-Luc vector was
transfected to cells for 24h, and cells were incubated in SF condition for 6h. After
washing with wash buffer (Promega, Madison, WI, USA), cells were lysed by lysis
buffer. Luciferase activity was determined by luminometer.
Measurement of cell viability and proliferation. MTT assay was
performed to examine cell viability. Cells were incubated in 0.5mg/ml of MTT
solution for 4h at 371C. After removing excess solution, precipitated materials were
dissolved in 200ml dimethyl sulfoxide and quantiﬁed by measuring absorbance at
540nm.
Immunoﬂuorescence staining. Cells grown on coverslips were washed
and ﬁxed with 100% Me-OH for 20min. After blocking with buffer (PBS/ anti-human
Ab (1:500)) to eliminate nonspeciﬁc binding, cells were incubated with primary
antibodies (1:200; OVN at 41C) and FITC-conjugated secondary antibodies at
371C for 1h. Nuclei were stained with 406-diamidino-2-phenylindole. After a ﬁnal
wash with PBS three times, coverslips were mounted with mounting solution
(H-5501; Vector Laboratories, Burlingame, CA, USA).
Patients and tissue samples. Our study enrolled a consecutive series of
489 patients with colorectal adenocarcinoma. All patients were diagnosed and
treated at the Hanyang University Hospital (Seoul, Korea) between January 1991
and August 2001. There were 272 male and 217 female patients. The mean age of
patients was 58 years. The tumors consisted of 463 non-mucinous
adenocarcinomas and 26 mucinous adenocarcinomas.
Tissue microarray construction. Tissue microarrays (TMAs) were
constructed from archival formalin-ﬁxed, parafﬁn-embedded tissue blocks using a
manual tissue arrayer (Quick-Ray Manual Tissue Microarrayer, Unitma Co. Ltd,
Seoul, Korea). As described previously,
29,34 for each sample, areas rich in tumor
cells were identiﬁed by light microscopic examination of hematoxylin–eosin-stained
sections and then selected for use in TMAs. Tissue cylinders with a diameter of
2mm were punched from the previously marked tumor area of each block (donor
block) and then transferred to a recipient parafﬁn block. This resulted in a 6 10
array for 60 cases.
Immunohistochemical staining. For immunohistochemical staining,
multiple 4mm sections were cut with a Leica microtome (Wetzlar, Germany).
Sections were transferred to adhesive-coated slides. TMA slides were dewaxed by
heating at 551C for 30min and by three washes, 5min each, with xylene. Tissues
were rehydrated by a series of 5min washes in 100, 90, 70% ethanol, and PBS.
Antigen retrieval was performed by microwaving the samples for 4min 20s at full
power in 250ml of 10mM sodium citrate (pH 6.0). Endogenous peroxidase activity
was blocked with 0.3% hydrogen peroxidase for 20min. The primary mouse
monoclonal Smad4 antibody (B-8; Santa Cruz Biotechnology) was diluted 1:250.
TheprimaryrabbitpolyclonalPAK1antibody(2602;CellSignalingTechnology)was
diluted 1:50. Then, they were incubated at room temperature for 1h. After three
washes, 2min each with PBS, the sections were incubated with a biotinylated goat
anti-mouse secondary antibody for 30min (DAKO, Glostrup, Denmark). After three
washes, 2min each with PBS, horseradish peroxidase-streptavidin (DAKO) was
added to the section for 30min, followed by another three washes, 2min each with
PBS. The samples were developed with 3,30-diaminobenzidine substrate (Vector
Laboratories) for 1min and counterstained with Mayer’s hematoxylin. Then, the
slides were dehydrated following a standard procedure and sealed with coverslips.
For negative control, Smad4 and PAK1 antibodies omitted during the primary
antibody incubation.
Interpretation of Smad4 and PAK1 immunostainings. Smad4 and
PAK1 expression was evaluated semiquantitatively by two independent
pathologists (Jang SM and Paik SS) without prior knowledge of the clinical
follow-up data for each case. On examination, each case was scored as having
normal, reduced, or loss of SMAD4 expression. Normal nuclear staining in the
epithelial cellslining normalcrypts orinﬂammatorycells inthemesenchymalstroma
on the same section served as an internal control (i.e., normal expression refers to
thesameexpressionasseeninthesecontrolcells).Lossofexpressionwasdeﬁned
as absence of nuclear staining. Reduced expression was graded when a weaker
expression, but not a complete absence of nuclear staining, was noted compared
with thecontrolcells.Theinterpretation of cytoplasmicPAK1expressionwas based
onstainingintensityandstainingextent.StainingintensityforPAK1wasscoredas0
(negative), 1 (weak), 2 (moderate), and 3 (strong). Staining extent was scored as
0(0%), 1 (1–25%), 2 (26–50%), 3 (51–75%), and 4 (76–100%) according to the
percentage of positively stained cells.
Statistical analysis. Statistical analysis was performed using SPSS software
(version 15.0, SPSS, Chicago, IL, USA). The w
2-test for linear trend and one-way
ANOVA test were used to examine the association between Smad4 and PAK1 and
clinicopathological parameters, including age, gender, tumor location, tumor size,
tumor type, T category, N category, AJCC stage, Dukes stage, and differentiation.
The Kaplan–Meier method was used to calculate overall survival and disease-free
survival curves. Univariate survival analysis with the log-rank test was used to
compare the difference between the survival rates of the patient subgroups.
Multivariate survival analysis with the Cox proportional hazards regression model
was used to evaluate the independent prognostic factors. A difference of Po0.05
between groups was considered signiﬁcant.
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